Answer these 30+ Patients, Patents, and Pharmaceutical Industry MCQs and assess your grip on the subject of Patients, Patents, and Pharmaceutical Industry.
Scroll below and get started!
A. Tippee
B. Temporary insider
C. Design patent
D. Intellectual property
A. Temporary insider
B. Design patent
C. Intellectual property
D. Evergreening
A. Intellectual property
B. Trademark
C. Intellectual work
D. Composition
A. Patent
B. Patent cliff
C. Process patent
D. Product patent
A. Patent
B. Patent cliff
C. Process patent
D. Product patent
A. Patent
B. Patent cliff
C. Process patent
D. Product patent
A. Articles of manufacture
B. Manufactured items
C. Manufactured products
D. Manufactured material
A. Nonexclusive
B. Universal
C. Nonspecific
D. Comprehensive
A. Utility patent
B. Patent cliff
C. Process patent
D. Product patent
A. True
B. False
A. Intellectual
B. Physical
C. Utility
D. Private
A. Individual
B. Intangible
C. Protected
D. Consumer
A. Secure
B. Intellectual
C. Investment
D. Utility
A. Both are concept goods.
B. Both are private goods.
C. Both are public goods.
D. Both are design goods.
A. Invention
B. Patent
C. Trademark
D. Copyright
A. Patent
B. Trademark
C. Copyright
D. Invention
A. Asset
B. Expression
C. Patent
D. Product
A. Patents are for hunting for a cure.
B. Patents should be possible in a competitive market.
C. Patents are for testing with or without useful results.
D. Patents that have no useful results are not acceptable.
A. Design, utility, and plant
B. Process, product, and plant
C. Public, utility, and process
D. Design, process, and product
A. Research, consistencies, and profits
B. Design, exclusiveness, and research
C. Utility, new, and nonobvious
D. Profits, relevance, and design
A. Plant
B. Process
C. Design
D. Utility
A. Product patent
B. Process patent
C. Trademark
D. Copyright
A. 22
B. 23
C. 21
D. 20
A. Profit
B. Innovations
C. Public
D. Marketing
A. Benkler
B. Cipla
C. Big Pharma
D. Shkreli
A. Design
B. Process
C. Product
D. Utility
A. Wiley Act
B. Federal Food Drug and Cosmetic Act
C. Import Drug Act
D. Orphan Drug Act
A. By requiring labeling requirements and warnings
B. By requiring drugs to be more affordable for patients
C. By requiring the rapid production of the drug
D. By requiring a delay in drug availability
A. The drug will no longer be effective.
B. Their product is no longer protected from competition.
C. The company will lose its trademark.
D. Their product is no longer available.
A. Decide if only blockbuster drugs are eligible
B. Be owned by the same developer
C. Modify the drug’s delivery mechanism
D. Be sure the product is outdated
A. Kept the price the same, knowing the drug was needed
B. Lowered the price of their drug to $9850 for profit
C. Lowered their price to $9,999 to keep up with the competitors
D. Made their product no longer available
A. Focus should be placed on lowering drug costs rather than emphasizing shareholders’ wealth.
B. Parties should agree to lower drug costs and make it easier for generic manufacturers to gain access to drug formulations.
C. Drugs should be donated to the consumers to keep the profit away from generic manufacturers.
D. It is appropriate to maintain high drug prices for maximum profits and to make it more difficult for generic manufacturers to gain access to drug formulations.
A. Composition
B. Purification
C. Stabilization
D. Conclusion
A. CDNA contains fewer genes.
B. CDNA is a product of nature.
C. CDNA is not a product of nature.
D. CDNA has no genes.
A. By proving patent right for 40 years
B. By providing low-interest loans
C. By privately funding the company
D. By providing federal funding of grants
A. Business
B. Personal
C. Group
D. National
A. Sympathomimetic
B. Sympatholytic
C. Parasympathomimetic
D. Parasympatholytic